亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion

医学 化疗 贝伐单抗 肺癌 内科学 肿瘤科 免疫疗法 癌症
作者
Yue Zheng,Yang Fu,Yueyun Chen,Qing Li,Ting Liu,Zhenyu Ding
出处
期刊:Current Oncology [Multidisciplinary Digital Publishing Institute]
卷期号:30 (11): 9929-9939 被引量:1
标识
DOI:10.3390/curroncol30110721
摘要

Background: EGFR and ERBB2 exon 20 insertion (Ex20ins) account for a small fraction of patients with EGFR mutations. The efficacy of immune checkpoint inhibitors (ICIs) for these patients was still controversial. Methods: This retrospective study enrolled lung cancer patients harboring either EGFR or ERBB2 Ex20ins mutations. All the patients were treated with platinum-based chemotherapy plus ICIs, or platinum-based chemotherapy. The demographic features and clinical outcome of each patient were reviewed and analyzed. Results: When treated with immunochemotherapy, patients with EGFR/ERBB2 Ex20ins mutations (n = 31) had poor PFS compared with those without EGFR mutations (n = 141, 5.0 mon and 11.2 mon, p < 0.001). When compared with those with EGFR classic mutations who received immunotherapy as the salvage therapy (n = 24), these patients with EGFR/ERBB2 Ex20ins mutations had similar PFS (5.0 mon and 4.1 mon, p = 0.625), ORR (37.5% vs. 48.4%), and DCR (70.8% vs. 77.4%). In the patients with EGFR/ERBB2 Ex20ins mutations, the PFS of those treated with chemotherapy (n = 54) and those treated with immunochemotherapy (n = 31) was 6.5 mon vs. 5.0 mon (p = 0.066). In the EGFR Ex20ins subgroup, the PFS of addition of bevacizumab to chemotherapy (n = 20) and chemotherapy alone (n = 16) was 8.8 mon and 5.2 mon, respectively (p = 0.082) or immunochemotherapy (n = 15, 8.8 mon and 5.0 mon, p = 0.097). Similarly, in the ERBB2 subgroup, the combination of bevacizumab and chemotherapy achieved a numerically longer PFS over chemotherapy alone (9.1 mon and 4.5 mon, p = 0.253), but there was no statistical significance. Conclusions: This study showed that platinum-based chemotherapy plus ICIs had limited efficiency compared to platinum-based chemotherapy for patients with EGFR/ERBB2 Ex20ins. Chemotherapy plus bevacizumab may be a potential scheme for these patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
凌七留下了新的社区评论
7秒前
9秒前
13秒前
pass完成签到 ,获得积分10
16秒前
17秒前
Dashwood完成签到 ,获得积分10
22秒前
大气金毛完成签到 ,获得积分10
28秒前
橘猫217发布了新的文献求助20
31秒前
白日梦发布了新的文献求助20
34秒前
ccc完成签到 ,获得积分10
39秒前
41秒前
科研通AI5应助科研通管家采纳,获得10
42秒前
半城微凉应助科研通管家采纳,获得10
42秒前
彭于晏应助科研通管家采纳,获得10
42秒前
李爱国应助科研通管家采纳,获得10
42秒前
王伟应助科研通管家采纳,获得10
42秒前
Akim应助科研通管家采纳,获得10
42秒前
科研通AI2S应助科研通管家采纳,获得10
42秒前
42秒前
43秒前
44秒前
lena发布了新的文献求助10
46秒前
量子星尘发布了新的文献求助10
58秒前
无与伦比完成签到 ,获得积分10
1分钟前
1分钟前
明理依云发布了新的文献求助10
1分钟前
1分钟前
搜集达人应助lena采纳,获得10
1分钟前
1分钟前
明理依云完成签到,获得积分10
1分钟前
1分钟前
HunterKK7发布了新的文献求助10
1分钟前
生动的如花完成签到,获得积分10
1分钟前
背后如彤完成签到 ,获得积分10
1分钟前
chrispaul完成签到,获得积分10
1分钟前
似画发布了新的文献求助10
1分钟前
。。发布了新的文献求助100
1分钟前
化羽归尘完成签到,获得积分10
1分钟前
顾矜应助lf采纳,获得10
1分钟前
化羽归尘发布了新的文献求助10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976600
求助须知:如何正确求助?哪些是违规求助? 3520700
关于积分的说明 11204482
捐赠科研通 3257320
什么是DOI,文献DOI怎么找? 1798683
邀请新用户注册赠送积分活动 877881
科研通“疑难数据库(出版商)”最低求助积分说明 806613